GENPREX INC (GNPX) Stock Price, Forecast & Analysis
NASDAQ:GNPX • US3724463027
GNPX Key Statistics, Chart & Performance
The current stock price of GNPX is 1.92 USD. In the past month the price decreased by -38.79%. In the past year, price decreased by -90.84%.
GNPX Technical Analysis
GNPX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNPX. While GNPX seems to be doing ok healthwise, there are quite some concerns on its profitability.
GNPX Financial Highlights
Over the last trailing twelve months GNPX reported a non-GAAP Earnings per Share(EPS) of -453.5. The EPS increased by 60.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -458.87% | ||
| ROE | -1262.44% | ||
| Debt/Equity | 0 |
GNPX Forecast & Estimates
GNPX Ownership
GNPX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.95 | 409.148B | ||
| AMGN | AMGEN INC | 16.51 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.21 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.97 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.84 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GNPX
Company Profile
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Company Info
GENPREX INC
3300 Bee Cave Road, Suite 650-227
Austin TEXAS 78712 US
CEO: J. Rodney Varner
Employees: 13
Phone: 18777744679
GENPREX INC / GNPX FAQ
What does GENPREX INC do?
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Can you provide the latest stock price for GENPREX INC?
The current stock price of GNPX is 1.92 USD. The price decreased by -4.95% in the last trading session.
Does GNPX stock pay dividends?
GNPX does not pay a dividend.
What is the ChartMill rating of GENPREX INC stock?
GNPX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in GENPREX INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNPX.